Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498440 | 0.85 | HCAR3 (0.66) | NPC1RAB9AALDH1A1DEGS1 | |
| SCHEMBL21061901 | 0.85 | HCAR3 (0.66) | NPC1RAB9AALDH1A1DEGS1 | |
| SCHEMBL18839009 | 0.85 | NPC1 (0.50) | NPC1RAB9AALDH1A1DEGS1MAPT | |
| SCHEMBL18839006 | 0.85 | NPC1 (0.50) | NPC1RAB9AALDH1A1DEGS1MAPT | |
| SCHEMBL30636222 | 0.81 | NNMT (0.51) | NNMTALDH1A1EPHX2 | |
| SCHEMBL29686685 | 0.81 | KMT2A (0.54) | NPC1RAB9AALDH1A1ABL1DEGS1 | |
| SCHEMBL25702959 | 0.80 | NPC1 (0.51) | NPC1RAB9AALDH1A1ABL1DEGS1 | |
| SCHEMBL28847350 | 0.80 | NPC1 (0.54) | NPC1RAB9AALDH1A1ABL1DEGS1 | |
| SCHEMBL29874618 | 0.80 | NPC1 (0.54) | NPC1RAB9AALDH1A1ABL1DEGS1 | |
| SCHEMBL5239807 | 0.79 | HCAR3 (0.68) | NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047928-B | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022105771-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2022-05-27 | — | — | WO | disclosed |
| CN-112047928-A | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NNMT 1562/4885NPC1 2064/4885RAB9A 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.